Published in Ann Surg Oncol on December 01, 1998
Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol (2012) 1.64
Primary anorectal melanoma. Case Rep Oncol (2014) 1.13
Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer (2010) 0.97
Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecol Oncol Rep (2016) 0.77
Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients. Medicine (Baltimore) (2017) 0.75
Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses. Clin Med Insights Case Rep (2017) 0.75
Controversies in the diagnosis and treatment of early cutaneous melanoma. J Med Life (2015) 0.75
A rare case of rynopharyngeal melanoma. Dent Res J (Isfahan) (2012) 0.75
Sinonasal malignant melanoma with diffuse carcinomatosis: initial PET/CT staging and follow-up CT/MR imaging. Radiol Case Rep (2015) 0.75
Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor. Int J Clin Oncol (2010) 0.75
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg (1998) 3.11
The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol (1989) 2.32
Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg (1990) 2.27
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol (2001) 2.01
Metastatic melanoma in the thorax: report of 130 patients. AJR Am J Roentgenol (1981) 1.95
Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg (1995) 1.90
Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. Surgery (1990) 1.72
MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol (1991) 1.60
Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery (1984) 1.59
Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg (1994) 1.56
Melanoma of the gallbladder: a review of cases seen at Duke University Medical Center. Cancer (1999) 1.54
Malignant melanoma and pregnancy. Cancer (1985) 1.47
Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia (2008) 1.46
Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg (1994) 1.41
Monoamine oxidase and catechol-O-methyltransferase activity in hamster and rat insulinomas. Diabetologia (1979) 1.41
Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. J Natl Cancer Inst (1993) 1.40
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res (1994) 1.38
Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet (1988) 1.38
Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci U S A (1984) 1.33
Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg (1988) 1.30
Skin graft rejection between subjects genotyped for HL-A. Transplant Proc (1969) 1.29
Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (1992) 1.28
Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery (1998) 1.28
Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg (1983) 1.26
Positron emission tomography scanning in malignant melanoma. Cancer (2000) 1.25
Central nervous system metastases in malignant melanoma. Neurosurgery (1981) 1.21
Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. J Natl Cancer Inst (1977) 1.18
Selection of patients for heterotopic implantation of the areola and nipple. Surg Gynecol Obstet (1980) 1.17
Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery (1993) 1.16
Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. Ann Surg (2001) 1.15
Anomalous MLR responsiveness among siblings. Transplant Proc (1971) 1.15
Hepatobiliary cystadenoma with mesenchymal stroma. Ann Surg (1990) 1.14
Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg (1992) 1.13
Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. Ann Surg (1989) 1.10
Incidence of anatomical variants in renal vasculature in the presence of normal renal function. Ann Surg (1978) 1.09
The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery (1991) 1.09
Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am J Surg (1991) 1.08
Ral activation promotes melanomagenesis. Oncogene (2010) 1.07
Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet (1983) 1.06
Non-specific and specific immunotherapy in patients with melanoma. Surgery (1972) 1.06
Renal transplantation between HL-A identical donor-recipient pairs. Functional and morphological evaluation. J Clin Invest (1972) 1.05
Primary malignant melanoma of the esophagus. J Surg Oncol (1997) 1.04
Immunogenetics of consanguineous allografts in man. II. Correlation of renal allografting with HL-A genotyping. Ann Surg (1970) 1.04
Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. Surgery (2000) 1.04
Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg (2000) 1.03
Malignant melanoma arising during pregnancy. A study of 100 patients. Ann Surg (1990) 1.03
Specific active immunotherapy for melanoma. Ann Surg (1979) 1.02
Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer (2000) 1.02
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer (1980) 1.02
Immunogenetics of consanguineous allografts in man. I. Histocompatibility testing and skin allografts. Ann Surg (1970) 1.01
Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery (1998) 1.00
The annual risk of melanoma progression. Implications for the concept of cure. Cancer (1992) 1.00
Malignant melanoma in black American and white American populations. A comparative review. JAMA (1982) 0.99
Subungual melanoma. A review of 93 cases with identification of prognostic variables. Clin Orthop Relat Res (2000) 0.98
Acral melanoma: a review of 185 patients with identification of prognostic variables. J Surg Oncol (1990) 0.98
Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. Cancer (1988) 0.98
Postoperative function of "free" jejunal transplants for replacement of the cervical esophagus. Ann Surg (1980) 0.97
Rejection of canine cardiac allografts. Am J Pathol (1968) 0.97
HL-A antigenic loss in malignant transformation. J Natl Cancer Inst (1971) 0.97
Current management of melanoma. Ann Surg (1977) 0.97
Prognosis for recurrent stage I malignant melanoma. Arch Surg (1987) 0.96
The immunogenicity of human HL-A haplotypesas measured by skin graft survival times and mixed leukocyte reactions. J Exp Med (1971) 0.95
Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. J Natl Cancer Inst (1988) 0.95
Radiologic, endoscopic and surgical considerations of malignant melanoma metastatic to the small intestine. Curr Surg (1984) 0.94
Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg (1992) 0.93
Cloacogenic carcinoma. Ann Surg (1978) 0.93
Long-term clinical outcome of immediate reconstruction after mastectomy. Plast Reconstr Surg (1985) 0.93
Pectoralis pyomyositis: an unusual cause of chest wall pain in a patient with diabetes mellitus and rheumatoid arthritis. J Rheumatol (1986) 0.92
Sex related survival differences in instances of melanoma. Surg Gynecol Obstet (1984) 0.92
Melanoma of the foot. J Bone Joint Surg Am (1994) 0.91
HL A typing, mixed leukocyte reactivity, and skin graft survival in a family with a recombinant at the HL-1 chromosomal region (major transplantation region). Transplantation (1973) 0.91
Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg (1993) 0.91
Percutaneous transluminal renal artery angioplasty in a 3 1/2-year-old hypertensive girl. J Pediatr (1980) 0.90
Anorectal melanoma: clinical characteristics and the role of abdominoperineal resection. Ann Plast Surg (1992) 0.90
Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol (2001) 0.90
A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer (1997) 0.90
Ileocolonic perforation. A complication following renal transplantation. Am J Roentgenol Radium Ther Nucl Med (1975) 0.90
Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg (2002) 0.90
Computed tomography in the detection of abdominal metastases from malignant melanoma. Invest Radiol (1984) 0.89
The spectrum of small bowel melanoma. Gastrointest Radiol (1978) 0.89
Lymphoscintigraphy for malignant melanoma. Surgical considerations. Am Surg (1983) 0.89
Rationale for immediate reconstruction of the breast following modified radical mastectomy. Ann Plast Surg (1982) 0.89
Graft donor selection based upon single locus (haplotype) analysis within families. Transplantation (1968) 0.88
Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res (1990) 0.88
Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. Cell Immunol (1996) 0.88
DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. Pancreas (1988) 0.87
The incidence and management of pulmonary mycosis in renal allograft patients. Ann Surg (1975) 0.87
Skeletal metastases of melanoma. J Bone Joint Surg Am (1978) 0.87
Long-term results with forty-five living related renal allograft recipients genotypically identical for HLA. Surgery (1977) 0.87
Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. J Surg Oncol (1988) 0.87
Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. Spine (Phila Pa 1976) (1995) 0.86
Sex steroid receptor analysis in human melanoma. Cancer (1980) 0.86
Biliary cystadenoma with mesenchymal stroma: CT and angiographic appearance. J Comput Assist Tomogr (1988) 0.86
Characterization of a chimpanzee anti-human melanoma antiserum. Cancer Res (1975) 0.86
Foregut carcinoids: a clinical and biochemical analysis. Surgery (1999) 0.85
Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. Cancer (2001) 0.85